SCD1 Confers Temozolomide Resistance to Human Glioma Cells via the Akt/GSK3β/β-Catenin Signaling Axis

Resistance to temozolomide (TMZ), the standard chemotherapy agent for glioblastoma (GBM), poses a major clinical challenge to GBM prognosis. Understanding the mechanisms of TMZ resistance can help to identify novel drug targets and more effective therapies. Recent studies suggest that bioenergetic a...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Front Pharmacol
Auteurs principaux: Dai, Shuang, Yan, Yuanliang, Xu, Zhijie, Zeng, Shuangshuang, Qian, Long, Huo, Lei, Li, Xuejun, Sun, Lunquan, Gong, Zhicheng
Format: Artigo
Langue:Inglês
Publié: Frontiers Media S.A. 2018
Sujets:
Pharmacology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5758607/
https://ncbi.nlm.nih.gov/pubmed/29354058
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2017.00960
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires